Treatment for chronic hepatitis C is based on combination therapy with pegylated interferon and ribavirin (RBV).1,2 One of the most important side effects of RBV is hemolytic anemia, which may require RBV dose reduction or discontinuation3 with a significant decrease in the rate of sustained virologic response (SVR).4 Little is known about the safety of RBV treatment in patients with concomitant glucose-6-phosphate dehydrogenase (G6PD) deficiency, who are inherently prone to hemolysis.5
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
CHESSA, LUCHINO;FARCI, PATRIZIA
2006-01-01
Abstract
Treatment for chronic hepatitis C is based on combination therapy with pegylated interferon and ribavirin (RBV).1,2 One of the most important side effects of RBV is hemolytic anemia, which may require RBV dose reduction or discontinuation3 with a significant decrease in the rate of sustained virologic response (SVR).4 Little is known about the safety of RBV treatment in patients with concomitant glucose-6-phosphate dehydrogenase (G6PD) deficiency, who are inherently prone to hemolysis.5
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
